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BUTYLPHENAMIDE; A NEW ANTI-FTJNGAL AGENT:
PRELIMINARY STTJDIES*
JOHN D. KRAFCHUK, M.D.t
T he persistent need for effective therapy of dermatomycoses spurs an increas-
ing search for, and evaluation of, new agents which offer promise of effective
clinical action and freedom from harmful or unpleasant side effects.
Since salicylic acid and salicylanilide have shown some degree of effectiveness
in the therapy of cutaneous fungus infections, a large number of related substi-
tuted salicylamides were evaluated in vitro in the hope of finding antifungal
agents of greater activity. N-n-butyl-3-phenyl-salicylamide (Butylphenamide)
demonstrated a marked effect in suppressing fungal growth, of an order much
greater than any of the agents presently employed in cutaneous fungus disease
therapy. More extended preliminary in vitro studies revealed the compound to
be both lethal and inhibitory, particularly to dermatophytes, effective in very
high dilution, even in the presence of serum, and free of the development of resist-
ance of the part of fungi tested. Oral, systemic, and cutaneous tests in experi-
mental animals revealed the compound to be remarkably free of toxic and irri-
tative properties. Clinical trial in 183 patients with skin disease revealed very
encouraging therapeutic effect and complete freedom from irritation. This report
presents a summary of these findings.
Summary of studies by other investigators on microbiology, pharmacology and toxicity of
But ylphenamide. Rather extansive microbiological, pharmacological, and toxicity studies
have bean conducted on Butylphenamide. In order to make this information easily avail-
able to dermatologists, it has been deemed justifiable to summarize it in some detail and
present it as a background for the clinical observations to be reported herein.
1. In vitro study of antifungal effects
A series of substituted salicylamides, synthesized by Jules et at. (1), were screened for
antifungal activity by bk et at. (2). Butylphenamide, which was inhibitory to Tricho-
phyton mentagrophytes in dilutions as high as 1:512,000 in Sabouraud's agar, and 1:64,000
in the presence of serum, was selected for further in-vitro study, to determine the extent
and nature of the anti-fungal action, and to compare effectiveness with other agents used
at present in treatment of fungus disease. The following data review these findings (2, 3).
a. Inhibitory effect of But ytphenomide on 9 pathogenic fungi affecting the skin. By incor-
porating serial concentrations of the Butylphenamide in tubes of culture media and inocu-
lating the surface with fungal suspensions, inhibitory effect on nine common skin pat hogens
was determined. Butylphenamide, which occurs in the form of non-hygroscopic crystals,
was first dissolved in propylene glycol as a 1% solution, from which serial dilutions were
prepared, and aliquots added to tubes containing Sabouraud's agar to yield the concentra-
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TABLE 1
The effect of Butoxyphenamid on growth of pathogenic fungi (from Ho/c (i))
Test Organism
Concentrations of Butyiphenamide (gamma/ml.)*
50 25 12 6 3 1.6 0.8 0.4
+++ +++
0.2
+++T.mentagrophytes.. - - - + +++ +++
T.rubrum - - - - + + ++ ++ +++
T.tonsurans - - - - - + ++ +++ +++
T.faviforme - - - - + ++ ++ +++ +++
M. audouini - - - - - + ++ ++ +++
M.canis - - - ++ ++ ++ ++ +++ +++
M.fulvum - - - - + + + + +++
Sporotrichum
schenkii + ++ +++ +++ +++ +++ +++ +++ +++
E.floccosum — — — — — — — + +++
No growth —, slight to full growth +, ++, +++.
* 1 gamma per ml. = 1 mg. per 1000 ml. = 1:1,000,000.
tions indicated in table 1. Control tubes with plain Sabouraud's agar and with only solvent
added were also included. Each tube was plated with suspensions of broken mycelia and
spores from three week old cultures of each of the fungi and examined for growth after 14
days of incubation at 30°C, recording partial, complete or no growth for each tube.
The results, indicated in Table 1, demonstrate the marked effect against the dermato-
phytes, all of which were completely inhibited by 12 gamma per ml. of media, the Epi-
dermophyton floccosum being affected by as little as 0.8 gamma per ml. The inhibitory effect
on the Sporotrichum schenkii strain was less marked. In the control tubes containing pro-
pylene glycol, (with concentrations greater than present in the tubes where it was used as
a solvent with Butylphenamide) slight retardation of growth was present during the first
week, but normal growth occurred thereafter.
b. The comparative in. vitro effect of Butylphenamide and 5 commonly employed anti-
fungal agents on 4 common dermatophytes. In a study employing similar technic, the in-
hibitory effect of Butylphenamide on dermatophytic fungi was compared with that exerted
by five commonly employed anti-fungal agents, appropriate solvents being used with each
chemical, as indicated in Table 2. Control tubes containing each of the solvents were in-
cluded, normal growth being noted with all.
The results, portrayed in Table 2, demonstrate the greater inhibitory effect exerted by
the Butylphenamide than noted with the other chemicals, for all 4 fungal species.
c. Inhibition by Butylphenamide and 4 other anti-fun gal agents in. the presence of com-
monly employed vehicles, with T. mentagrophytes. Since anti-fungal agents must be incor-
porated in a vehicle for clinical use, a study, employing similar technic, was carried out
to determine the influence of such vehicles on inhibitory effect. Preparations tested in-
cluded Butylphenamide as an ointment, lotion and tincture, Sopronal, Asterol, and Dese-
flex as ointments and solutions, and Whitfield's ointment. Each preparation was incorpo-
rated in Sabouraud's agar, to give 10 dilutions for each ranging from 1:50 to 1:64,000. T.
noentagrophytes was employed as the test organism.
The Butylphenamide preparations were completely inhibitory in dilutions of 1:16,000,
1:2,000, and 1:16,000 for the ointment, lotion, and tincture respectively. The Sopronol
ointment and solution were both inhibitory at 1:2,000, the Asterol preparations both at
1:500, and the Desenex both at 1:4,000. The Whitfield ointment tube showed inhibition at
1:500. Thus while all preparations showed some decrease of inhibitory effect with the
inclusion of vehicular materials, the Butylphenamide remained more active than the
other preparations, and in high dilution.
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TABLE 2
Inhibitory action of But ylphenamide and five other compounds against representative
dermatophytes (from Hole (2))
Growth Inhibition Concentrations (gamma/mi.)
Compound Test Organism ... __________ ___ ——
50 25 12 6 3 1.6 0.8 0.4 0.2
Butyiphenamide (giyeoi) T. mentagrophytes + +
T.rnbrum + + +
M.audouini + + +
M.eania — — — — + + + +
Diamthazoi ("Asterol") (water) T. mentagrophytea + + + ++ ++ +++ +++ +++
T.rubrum + + + ++ ++ ++ ++ ++
M. audouini + + + ++ ++ ++ ++ ++
M.eanis + + + ++ ++ ++ ++ +++
Salinyhe arid (ethanol) T. mentagrophytes +++ +++ +++ +++ +++ +++ +++
T. rubrnm ++ +++. +++ +++ +++ +++. +++
Ii. audonini +++ +++. +++ +++ +++ +++. +++
M. eanis ++ +++. +++ +++ +++ +++. +++
Undeeylinie acid (ethanol) T. mentagrophytea — ++ +++ +++• +++
T. rubrum + ++ +++ +++ +++
M. audouini - ++ +++ +++ +++
M.eania - + ++ +++ +++
Copper undeeylinate (ethanol) T. mentagrophytea — + ++ +++ +++
T. rubrum - ++ +++ +++ +++
ST. audnuini + +++ +++ +++ +++
ST. eania - + +++ +++ +++
Sodium propionate (water) T. mentagrophytea +++ +++ +++ +++ +++ +++ +++ +++
T. robrum +++ +++ +++ +++ +++ +++ +++. +++
ST. audouini +++ +++ +++ +++ +++ +++ +++ +++
ST. rania +++++++++++++++++++++ +++
No growth: —, trace to normal growth +—, +, ++, +++.
Controla: plain Sahouraud'a agar, 2.5% giyeoi, 2.5% ethanol. +++, I nil growth for all apeeiea.
d. The effect of serum on the inhibitory activity of But ylphenamide. Since body fluids may
interfere with anti-fungal activity of some chemicals, a study employing similar technic,
was carried out to determine the effect of serum on growth inhibition. Parallel series were
observed, without and with serum (in a concentration of 10%) consisting of 9 dilutions of
Butylphenamide ranging from 50 to 0.2 gamma per ml. of culture medium and two test
organisms, T. mentagrophytes and T. rubrum. For the T. mentagrophytes, complete and
partial inhibition were noted at 1.6 gamma/ml. and 0.2 gamma/ml. with the plain media
(without serum), and 25 gamma/ml. and 3 gamma/mi. for the serum-agar. With the T.
rubrum, the comparable values were 3 gamma/ml. and 1.6 gamma/ml. for the plain agar
and 25 gamma/mI. and 3 gamma/ml. for the serum-agar. Thus, while some decrease in
effect is noted in the presence of serum, the chemical remains inhibitory in very high dilu-
tion.
e. In vitro effect of Butylphenamide against other fungi and bacteria. In a limited pilot
evaluation, the effect of Butylphenamide was determined for a miscellaneous group of
saprophytic fungi, yeasts, and bacteria employing a technic similar to that in the stud-
ies described above. No appreciable inhibition was noted for Bacillus subtilis, Escherichia
coli, Saccharomyces cerevisiae, Torula species (BR-155), Candida albicans, Aspergillus
niger, Penicillium species (BR-156), and Stroptomyces species (AR-iSO). Significant inhibi-
tion of Mycobacterium 607, a saprophyte, occurred, but was not duplicated with patho-
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genie species. The inhibitory effect of the Butyiphenamide, then, based on preliminary
observations, appears to be directed particularly against the dermatophytes.
f. In vitro demonstration of fungicidal action by But ylphenamide. In order to determine
whether the drug was fungicidal as well as fungistatic, aa in vitro study was carried out
using T. mentagrophytes and M. audouini as test organisms. Fragmented mycelium and
spore suspensions were prepared for each organism, and aliquots inoculated into serial
dilutions of the chemical ranging from 100 to 0.4 gamma/mi. At intervals of 6, 24, and 72
hours, 0.1 mi. from each tube was transferred to Sabouraud's broth and observed for growth
over 14 days. 3.2 gamma per ml. of the compound was found to be lethal for the T. menta-
grophytes, and 0.8 gamma per ml. for the M. eudouini. For both organisms, lethal effect
was complete by 6 hours.
g. Determination of the development of in vitro resistance to But ylphenamide by Dermato-
phytes. In order to determine whether resistance to Butyiphanamide might develop in
susceptible organisms, an appropriate in vitro study with T. mentagrophytes and M. au-
douini was carried out. Parallel series with diamethazol and Na-undecylenate were in-
cluded, for comparative purposes. Tubes of culture media containing serial dilutions of
the chemical substances tested were inoculated with suspensions of organisms and observed
for growth. Material from the growth in tubes containing the highest concentration of
chemical were then transferred to new series of tubes of culture media with the same serial
dilutions of the chemicals. This subculture technic was carried on for 9 successive transfers
at 14-day intervals over a 4-month period. At the end of that time, inhibitory concentra-
tions were compared with those originally noted. With both fungus species, no change in
inhibitory concentrations was observed with Butylphenamide. The results with the other
two chemicals, though somewhat irregular, suggested that twice the original concentra-
tions were necessary to produce comparable inhibition.
In summary, Butylphenamide demonstrated both fungistatic and fungicidal activity
in high dilution, specifically for the Dermatophyte group of fungi of those tested, compar-
ing very favorably with anti-fungal agents employed clinically at present. Anti-fungal
effect persisted with the addition of several types of material to the media, and no resist-
ance to action developed in a limited study.
2. Animal toxicity studies
An extensive series of studies to determine possible toxicity of Butylphenamide were
carried out by Dr. V. P. Seeberg (4) of the Cutter Laboratories, employing mice, rats and
rabbits. The following data review his findings.
a. Acute toxicity studies. The LD50 of the Butylphenamide by the intraperitoneal route
was found to be 1.85 Gm. per Kg. in mice and 2.4 Gm. per Kg. in rats, which, weight for
weight, would approximate 100 Gm. for a 50 Kg. human adult. Orally, in mice and rats,
no toxicity could be produced. Doses below 16 Gm. per Kg. produced no toxicity, and
more than that amount caused regurgitation. In rabbits, no toxicity was noted up to 3.2
Gm. per Kg., at which level regurgitation similarly occurred.
b. Subacute toxicity studies with prolonged oral administration of Butylphenamide (Byna-
mid) to rats. A group of 60 Sherman-Wister rats, half male, half female, were divided into
three groups, the first receiving orally 0.3 Cm. per Kg. daily (equivalent to 15 Gm. for 50
Kg. adult), the second 1.0 Gm. per Kg. daily (equivalent to 50 Gm. for 50 Kg. adult), and
the third group given none of the chemical, as controls. Adequate measures were taken to
make certain all of the chemical was ingested daily. Some of the animals of each group
were autopsied after 30 days, the others after 90 days. Pre-treatment and final examinations
of blood and urine were carried out with all animals. Postmortem examinations for all in-
eluded gross and/or microscopic examination, as indicated, of the heart, adrenals, spleen,
kidneys, lungs, liver, stomach, intestines, pancreas, gonads, brain, and heart blood. In no
instance was any abnormality found.
c. Skin irritation studies. In a "small area" study, 1 inch square patches on the flanks
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of young albino rabbits were coated with 2% or 10% ointments daily (five days weekly)
for two-week periods, the animals being kept in stocks for eight hours after each applica-
tion to prevent scratcbing. No instance of local irritation was observed.
In a "large area" study, 4 Gm. per Kg. of the Butylphenamide was applied as oint-
ment to 20% of the body surface daily (five days weekly) for four weeks, the animals being
similarly immobilized for eight honrs after each application to prevent scratching. Studies
of the hemogram, blood coagulation, sedimentation rate, and nrine were carried out be-
fore and after the four-week period in all animals. No changes were noted. Postmortem
examination of all animals revealed no gross or microscopic abnormalities in any of the
principal organs or the treated skin.
d. Absorption and distribution in tissues. In rabbits, the intramuscnlar injection of 100
mg. per Kg. of Butylphenamide as a 10% aqueous suspension was followed by the appear-
ance of only traces of the compound in the serum, indicating little or no absorption from
this site.
Oral administration of 1 Gm. per Kg. as an aqueous suspension to fasted rabbits led to
maximum levels of only 1 gamma per ml. in the serum. This minimal absorption is no doubt
responsible for the lack of toxicity noted with oral administration.
With the compound prepared as a 10% solution in a vehicle consisting of 25% Tween
80, 25% propylene glycol, and 50% water, oral administration resulted in somewhat greater
absorption. In this form, administration of 0.5 Gm. per Kg. was followed by peak serum
levels of up to 18 gamma per ml. at 90 minutes. Rabbits given 0.25 Gm. per Kg. of the com-
pound in the Tween 80-propylene glycol vehicle were sacrificed after 90 minutes and tissue
levels measured. Highest values (up to 334 gamma per ml.) were found in the urine, lesser
concentration (up to 14 gamma per ml.) in the kidneys and liver, and minimal detectable
levels in the skin, muscle, brain, and serum. The total of these values, measured in gamma,
represent only a very minute percentage of the total administered dose, virtually 100%
of the ingested material having been found in the contents of the gastro-intestinal tract.
In summary, Butylphenamide (Bynamid) was found to be essentially free of any de-
tectable toxic, irritative, or sensitizing properties in the experimental animals tested.
3. Nature of the material
The N-n-butyl-3-phenyl-salicylamide (Butylphenamide) occurs in the form
of colorless, non-hygroscopic needles, and, pulverized to a fine powder, is readily
snspended in 1 % tragaenth solution for incorporation in various vehicles for
clinical use. For quantitative determinations of Butylphenamide in fluids or
tissue, dilute solutions in water and various organic solvents emit a strong
fluorescence with light from a monochromator at wave lengths below 37000,
permitting accurate measurement of very minute concentrations, by means of a
sensitive fiuorophotometer (3).
4. Clinical results
Butylphenamide, in ointment, tincture, and water soluble bases, was employed
in the treatment of skin disease in 183 patients, for whom adequate follow-up was
possible*, over a nine-month period. Subjects were selected, with fungus infec-
* A number of patients, given Butylphenamide for treatment of skin diseases in the
categories listed, did not return for subsequent appointments. With some of these, tele-
phone calls or later visits for unrelated problems indicated that many or most did not
return because of complete and rapid resolution of the treated skin lesions. Thus the thera-
peutic results may he considered to be actually better than here indicated.
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tions of the skin or chronic dermatoses, from a consultation dermatology clinic
of a large military hospital. Patients included military personnel (96 cases), de-
pendents (79 cases), retired military personnel (7 cases), and civilian workers
(3 cases). 130 were males, 53 females. According to age distribution, there were
36 patients below 10 years of age, 40 from 11 to 20, 54 from 21 to 30, 30 from 31
to 40, 9 from 41 to 50, 10 from 51 to 60, and 4 from 61 to 70. All patients were
seen initially and in all subsequent visits by the single reporting physician.
Scrapings and cultures for fungi were carried out in all instances. Punch
biopsies of the affected skin were taken both before and after onset of Bynamid
therapy in many of the patients; none of these showed any histologic changes
other than considered related to the disease treated. Frequent photographs were
made to permit objective comparison of progress. Laboratory studies of blood
and urine were carried out in most patients both before and during therapy; in
no case was any alteration noted.
The use of either tincture (5% or 10%), ointment (5%) or water soluble base
(5 %) was based on random choice; most of the cases were treated with either
the tincture or ointment, the water soluble base becoming available only late in
the study. While the results with each type of base are not indicated in the
tables because no significant differences were noted, the tincture in general ap-
peared more rapidly effective, particularly in suppression of itching, which often
occurred instantaneously with application. In all instances, the patients were
instructed to clean the area involved once daily, usually with a damp cloth, and
to apply the material locally in liberal quantities three or four times daily. In all
cases, no other therapy, local or systemic, was given during the period of ob-
servation. In cases of eczema, the patients were instructed to avoid possibly
irritative substances.
a. Dermatomycoses. 98 patients with fungus infection of the skin were treated
with Butylphenamide, the specific categories listed in table 3. Most of these had
failed to respond to other modes of therapy, either as self-treatment or by other
clinics or physicians. With infection of other than hair or nails, therapy was
usually kept up for two to three weeks before final evaluation of results, although
many cases responded dramatically in a matter of a few days. With hair and nail
infection, treatment continued daily for up to four months before final evalua-
tion, the patients being checked at two-week intervals for clinical effect. In pa-
tients with tinea capitis, the presence or absence of fluorescent hairs was used as
a criterion of cure. In a few instances, where results with one form of Bynamid
showed no effect, a change was made to another form.
Of the cases of tinea capitis, 5 represented infection with M. canis, (most
favorable response) and 5 with M. audouini. Of the cases of tinea corporis, 8
were due to M. canis infections, part of a small local epidemic apparently spread
by derelict cats, from the hair of one of which M. canis was cultured. The other
tinea infections consisted mainly of trichophyton infections except for 8 of the
cases of tinea cruris which were due to Epidermophyton floccosum. The specific
organisms are not tabulated separately in relation to clinical response, since
clinical results did not correspond to types of etiologic fungi.
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TABLE 3
Response of patients (numbers of cases) with dermatomycoses treated with But ylphenamide































































Totals 89 32 22 17 16(5) 2(1)
* Worsened after initial use of Butyiphenamide; subsequent use caused no reaction.
f Tincture caused burning, ointment well tolerated.
subsequently treated with other form of Butyiphenamide, relisted.
The results of therapy are listed in table 3. Of the total of 89 cases, 32 were
completely well, and 22 well except for slight residual erythema and/or thicken-
ing of the involved skin. 16 others showed definite improvement. It should be
recalled that many of these cases had not responded to other forms of treatment.
In addition, when failure with Butylphenamide was noted, subsequent treatment
with other forms of therapy produced greater clinical effect in only a few in-
stances.
It is noteworthy that where itching was present, almost all patients described
almost immediate and complete relief with application of the Butylphenamide,
particularly where the tincture was used. Many patients were kept free of itching
by repeated application of the Bynamid whenever slight itching recurred, usually
noted after several hours. This was observed even where complete clinical im-
provement did not occur. This anti-pruritic effect suggested use of the com-
pound in the treatment of chronic dermatoses.
When relapse occurred after cessation of therapy, noted in many instances
within a week or two, repeated application of Bynamid at the first sign of itching
or redness usually resulted in sustained remission.
No instances of sensitivity or definite irritation were observed. In the few
instances where worsening occurred following local application of the Butyl-
phenamide, it was considered a phase of the natural course of the disease, since
subsequent application to the involved areas after the acute phase subsided
failed to produce any local reaction.
It was felt that the results, while perhaps not as dramatic in all cases as might
be hoped for from the marked in vitro effects, were superior to those observed
when other commonly used anti-fungal agents were employed.
b. Inflammatory dermatoses. Because of the relief of itching noted, and the
results observed in some cases of chronic fungus infection of the skin, a group of
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TABLE 4
Response of patients (numbers of eases) with chronic inflammatory dermatoses treated with
But ylphenamide
























































Totals 71 11 25 14 20 1
* Worsened after initial use of Butyiphenamide; subsequent application caused no re-
action.
Subsequently treated with other form of Butyiphenamide, relisted.
patients with common chronic dermatoses was selected for therapy with Butyl-
phenamide. Most of these had failed to improve with other types of treatment,
for periods of weeks or months. 71 patients were included in this group, the
diagnostic categories listed in table 4.
It will be noted from the results presented in table 4 that approximately 50 %
of the cases were markedly benefited, 11 becoming completely well, and 25 almost
well, with only slight residual erythema and/or local thickening or itching. The
most favorable results were observed with localized patches of itching eczema
(lichen chronicus simplex) where, of 31 cases, 9 rapidly cleared completely and 10
showed almost complete clearing. Chronic eczema of the hands also showed very
encouraging results, some of the cases responding dramatically.
In cases where it was present, rapid and marked relief of itching was observed
following the local application of Butylphenamide, usually lasting several hours,
and sustained with repeated application.
When relapse occurred following cessation of therapy, re-use of Butylphena-
mide routinely produced results comparable to those originally noted. By applying
the material immediately with re-appearance of slight erythema or itching,
sustained remission could be achieved.
In only one patient, a child with infantile eczema, was local application of
Butyiphenamide followed by worsening of the dermatitis. This, too, was felt to
represent part of the natural course of the disease, since re-application of Butyl-
phenamide locally after subsidence of the acute phase produced no notable reac-
tion.
c. Miscellaneous group of skin diseases. In view of the favorable results noted
in fungus infections of the skin and chronic dermatoses, Butylphenamide was
used therapeutically in an unselected group of skin diseases that had shown in-
complete response to standard methods of therapy. This pilot study, on a small
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group, included 6 cases of psoriasis, 4 of pityriasis rosea, 4 of verruca vulgaris, 2
of lichen planus, and 1 each of parapsoriasis, mulluscum contagiosum, alopecia
areata, pyogenic sycosis barbae, dermatitis herpetiformis, and severe palmar
hyperkeratosis. No significant effects were noted in any of these, except for al-
most complete clearing in the case of palmar hyperkeratosis, which had shown
no response to other therapy over a period of years.
5. Summary and conclusions
In preliminary studies of a new anti-fungal agent, Butyiphenamide, bk et al.
(2, 3) and Seeberg et al. (4) have demonstrated: (1) the highly potent anti-fungal
activity in-vitro, particularly against the dermatophytes, of an order much
greater than noted with any of the compounds presently used in treatment of
cutaneous fungus disease; and (2) the absence of toxic or unpleasant side effects.
Presently reported clinical trials on 183 patients with fungus infections, chronic
dermatoses, and a miscellaneous group of skin diseases have shown that this drug
has a very favorable effect on some fungus infections of the skin and localized
eczemas. The suppression of itching in many patients, even when complete
clinical cure did not occur, afforded a welcome symptomatic response.
The results of these preliminary studies warrant the use of this material on
a more extensive scale, necessary before the ultimate role of this compound in
dermatologic therapy can be established. The absence of sensitization and irri-
tation in this preliminary study are particularly encouraging.
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